ImmunityBio
IBRX
47 hedge funds and large institutions have $21.8M invested in ImmunityBio in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.
232% more capital invested
Capital invested by funds: $6.57M → $21.8M (+$15.2M)
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
21% more funds holding
Funds holding: 39 → 47 (+8)
0.36% more ownership
Funds ownership: 5.48% → 5.84% (+0.36%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
70% less call options, than puts
Call options by funds: $94K | Put options by funds: $309K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$544K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$237K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$226K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$215K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$600K |
| 2 |
HKAM
Horizon Kinetics Asset Management
New York
|
-$250K |
| 3 |
Millennium Management
New York
|
-$186K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$58K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$28.9K |
IBRX Hedge Fund Activity: Q4 2019 in Review
47 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2019, worth a combined $21.8M — up 232% from $6.57M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IBRX positions and 6 closed out — a net gain of 8 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $544K. The largest seller was Wildcat Capital Management, exiting entirely with an estimated $600K sold.
- 47 institutional investors held ImmunityBio (IBRX) as of Q4 2019, up from 39 in Q3 2019.
- Funds reported $21.8M of ImmunityBio stock for Q4 2019, up 232% quarter-over-quarter.
- 14 funds opened new ImmunityBio positions in Q4 2019 and 6 closed out, a net change of +8 holders.
- The largest ImmunityBio buyer in Q4 2019 was BlackRock, an estimated $544K added.
- The largest ImmunityBio seller in Q4 2019 was Wildcat Capital Management, an estimated $600K sold.
Based on aggregated 13F filings for Q4 2019.